A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas Article

cited authors

  • Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B; Chang, Susan M; Lamborn, Kathleen R; Kuhn, John G; Yung, WK Alfred; Gilbert, Mark R; Aldape, Kenneth D; Wen, Patrick Y; Fine, Howard A; Mehta, Minesh; DeAngelis, Lisa M; Lieberman, Frank; Cloughesy, Timothy F; Robins, H Ian; Dancey, Janet; Prados, Michael D

fiu authors

publication date

  • January 1, 2010

keywords

  • BRAIN-TUMOR CONSORTIUM
  • CELLS
  • COMMON
  • CONFERS ENHANCED TUMORIGENICITY
  • Clinical Neurology
  • GROWTH-FACTOR RECEPTORS
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • PHARMACOKINETICS
  • Science & Technology
  • TEMOZOLOMIDE
  • TYROSINE-KINASE INHIBITOR
  • erlotinib
  • glioblastoma
  • glioma
  • meningioma
  • pharmacokinetics

Digital Object Identifier (DOI)

start page

  • 87

end page

  • 94

volume

  • 12

issue

  • 1